Abstract

In the current COVID-19 era, one of the critical factors influencing the quality of hospital services is drug management, with planning and procurement being particularly pivotal to avoid drug shortages. This study aimed to examine the selection, procurement, and lead time aspects of drug management at the pharmacy installation hospital in Jakarta during the COVID-19 pandemic. Conducted as a descriptive study with retrospective data, total sampling was utilized to collect data, incorporating 1,413 drugs. The data, collected on observation sheets, underwent univariate analysis using Microsoft Excel. Results indicated that out of the seven measurable indicators, two met the standards: the percentage of allocated funds for drug procurement at 70.5%, and the frequency of errors in orders occurring five times. However, five indicators fell below the standards: the suitability of drug items with the National Formulary at 14.15%, the suitability of drug items with the Hospital Formulary at 68.15% (with an 80% benchmark), the frequency of each item's procurement in a year at a low category of 43.45%, the percentage of conformity between planning and reality at 99.61%, and the achievement of lead time for ordering drugs at 5.08 days. In conclusion, the selection, procurement, and lead time aspects of drug management at the "X" Hospital Pharmacy Installation did not fully meet the established standards. Therefore, it is recommended that healthcare management implements and adheres to robust drug management system regulations, particularly during pandemic situations, to ensure optimal hospital services.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.